Internal Medicine

Rutgers

Questions discussed in this category

What is your preferred second line therapy for an HCC patient who progressed after first line checkpoint inhibitor monotherapy?

Would you try atezolizumab/bevacizumab or switch to a TKI?

2 Answers available

Are you routinely using thrombopoietin agonists in patients with hep C and HCC?

If so, for what platelet count threshold and do you have a preference as to which agent?

1 Answer available

Papers discussed in this category

Gastroenterology, 2018 May 17

Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.

Clin. Gastroenterol. Hepatol., 2018 Nov 28

Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.

Hepatology (Baltimore, Md.), 2019-10

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).

The New England journal of medicine, 2018-07-05

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Lancet (London, England), 2018-03-24

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

J Gastroenterol, 2019 Nov 12

REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.

Am Heart J, 2010 Sep 18

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

N Engl J Med,

Sorafenib in advanced hepatocellular carcinoma.

Lancet (London, England), 2017-01-07

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology, 2019-02

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

JAMA Oncol, 2020 Dec 10

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.

Hepatology, 2019 Oct 14

Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Related Topics in Internal Medicine